Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 892 across all filing types
Latest filing 2019-04-18 Annual Report
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Annual Report 2018
Annual Report Classification · 100% confidence The document is titled 'Annual & Sustainability Report 2018' and contains comprehensive sections including a CEO letter, business overview, financial statements, auditor's report, and sustainability disclosures. It covers the full fiscal year 2018 and provides detailed financial data, making it a primary annual report rather than an announcement or a summary. FY 2018
2019-04-18 English
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
AGM Information Classification · 100% confidence The document is explicitly titled "Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)" and details the date, time, location, procedures for participation (including proxy rules), and the proposed agenda for the meeting. The agenda items cover standard AGM topics like electing the chairman, approving the agenda, receiving reports, voting on profit appropriation, and electing/determining fees for the Board of Directors and auditor. This content perfectly matches the definition of an Annual General Meeting document. Therefore, the classification is AGM-R.
2019-04-03 English
Kallelse till årsstämma i Swedish Orphan Biovitrum AB (publ)
AGM Information Classification · 99% confidence The document is titled "Kallelse till årsstämma i Swedish Orphan Biovitrum AB (publ)" which translates to "Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)". It details the date, time, location, registration procedures, proposed agenda items (including election of board members, approval of remuneration guidelines, and proposals regarding capital structure), and specific proposals related to shareholder votes and governance structures (like the Nomination Committee instructions). This content is characteristic of a formal notice and materials distributed for an Annual General Meeting (AGM). The presence of a detailed agenda and proposals for shareholder votes strongly points towards AGM materials, which aligns best with the AGM Information (AGM-R) code. It is not a full 10-K, an earnings release (ER), or a proxy statement (PSI), but specifically the notice for the AGM.
2019-04-03 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive 'Q4 and full-year report 2018' for Sobi. It contains detailed financial statements, performance metrics, management commentary, business reviews, and operational highlights for the specified fiscal period. It is not an announcement of a report (RPA) nor a simple earnings release (ER), as it provides extensive financial data and analysis consistent with an interim/quarterly report. Q4 2018
2019-02-20 English
Earnings Release 2018
Earnings Release Classification · 99% confidence The document contains detailed financial figures for the fourth quarter (Kv4) and the full year (Helår) of 2018, including revenue, EBITA, EPS, and segment performance (Haemophilia, Specialty Care). It also includes management commentary ("Vd har ordet") and outlook for 2019. The presence of comprehensive financial tables, year-over-year comparisons, and a CEO statement strongly indicates a full financial report covering a fiscal period. Since the text covers the full year's performance and is highly detailed, it aligns best with an Annual Report (10-K) or a comprehensive Interim/Quarterly Report (IR). Given the Swedish context and the date (February 20, 2019), this is likely a year-end report. While it contains the depth of a 10-K, in many non-US contexts, the most comprehensive annual report released outside of the formal 10-K filing structure is often classified as an Annual Report (AR) or, if it's the primary financial disclosure, it might be treated as the equivalent of a 10-K if it covers the full year. However, the definitions provided distinguish between 10-K (Official yearly report) and AR (Standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests). Since this document is a comprehensive financial communication covering the entire fiscal year, it functions as the primary annual financial disclosure. If a specific 'Annual Report' code existed for comprehensive year-end results that aren't strictly the SEC 10-K, AR might fit, but 10-K is defined as the 'Official yearly report covering company activity and full financial performance.' Given the comprehensive nature covering the full year, 10-K is the most appropriate fit among the options for a full-year financial disclosure, even if the source language is Swedish. If this were only Q4, IR would be better, but it explicitly covers 'helåret' (full year). Q4 2018
2019-02-20 Swedish
Sobi publicerar bokslutskommunikén för 2018
Earnings Release Classification · 99% confidence The document contains detailed financial figures for the fourth quarter (Kv4) and the full year (Helår) of 2018, including revenue, EBITA, EPS, and segment performance (Haemophilia, Specialty Care). It also includes management commentary ("Vd har ordet") and outlook for 2019. The presence of comprehensive financial tables, year-over-year comparisons, and a CEO statement strongly indicates a full financial report covering a fiscal period. Since the text covers the full year's performance and is highly detailed, it aligns best with an Annual Report (10-K) or a comprehensive Interim/Quarterly Report (IR). Given the Swedish context and the date (February 20, 2019), this is likely a year-end report. While it contains the depth of a 10-K, in many non-US contexts, the most comprehensive annual report released outside of the formal 10-K filing structure is often classified as an Annual Report (AR) or, if it's the primary financial disclosure, it might be treated as the equivalent of a 10-K if it covers the full year. However, the definitions provided distinguish between 10-K (Official yearly report) and AR (Standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests). Since this document is a comprehensive financial communication covering the entire fiscal year, it functions as the primary annual financial disclosure. If a specific 'Annual Report' code existed for comprehensive year-end results that aren't strictly the SEC 10-K, AR might fit, but 10-K is defined as the 'Official yearly report covering company activity and full financial performance.' Given the comprehensive nature covering the full year, 10-K is the most appropriate fit among the options for a full-year financial disclosure, even if the source language is Swedish. If this were only Q4, IR would be better, but it explicitly covers 'helåret' (full year). Q4 2018
2019-02-20 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.